-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics (SMMT) Stock Looks Above Fair Value On Book Value

Simply Wall St·11/16/2026 21:14:56
Listen to the news

Summit Therapeutics has seen sharp swings in sentiment after mixed regulatory news around its lead cancer drug, which puts a fresh spotlight on whether the current share price lines up with the value on its balance sheet. For investors watching a volatile chart and a developing drug pipeline, the open question is how far that book value can anchor expectations for the stock.

  • Over the past 3 years, Summit Therapeutics has delivered a very large share price gain, which puts more weight on whether the underlying net assets can support that kind of move.
  • The recent FDA rejection of ivonescimab for a lung cancer use, alongside ongoing trials and a large equity investment from AstraZeneca, may reshape expectations for future capital needs and the pace at which Summit Therapeutics can translate its research into revenue producing assets.
  • Your read on Summit Therapeutics is one view; the desks covering it have another. See what analysts think Summit Therapeutics's shares could be worth.

The issue now is whether Summit Therapeutics’ current market value is adequately backed by its book value once you strip the story down to the balance sheet.

If you want to test the same book value question beyond Summit Therapeutics, compare this story with companies in the 35 high quality undervalued stocks.

Does Summit Therapeutics Look Pricey on Book Value?

P/B works well for Summit Therapeutics because the balance sheet is one of the few hard anchors investors can reach for while the pipeline is still pre revenue. On this yardstick, the stock trades on a P/B of 20.0x, compared with a Biotechs industry average of about 1.8x and a peer group closer to 7.1x. That is a very large premium to both reference points, which points to an overvalued reading on this multiple.

The recent FDA rejection of one lung cancer use for ivonescimab has not pulled the P/B ratio anywhere near sector norms, so the market is still assigning a rich valuation to Summit Therapeutics relative to its net assets. For you as a shareholder or potential buyer, the question is whether the drug portfolio and AstraZeneca partnership justify paying so far above the industry’s usual price for each dollar of equity. Explore the numbers behind Summit Therapeutics's P/B valuation.

NasdaqGM:SMMT P/B Ratio as at Nov 2026
NasdaqGM:SMMT P/B Ratio as at Nov 2026

The Summit Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Summit Therapeutics pick up where the book value puzzle leaves off and explain what future growth, profitability and earnings outcomes would need to hold for the shares to be worth materially more or materially less than today's market price. Each storyline links a fair value estimate to a specific mix of potential catalysts and risks around Summit Therapeutics' pipeline and funding path so you can track over time which version of events is actually unfolding.

Views on Summit Therapeutics split sharply, with one camp arguing the valuation underplays ivonescimab’s reach and another seeing spending and dilution setting a ceiling.

Bull case: 66% undervalued

This view comes from the bullish analyst Narrative on Simply Wall St, which leans on optimistic forecasts for ivonescimab and partner support.

"Results from the HARMONi‑GI1 biliary tract cancer study, which showed a 25% reduction in risk of death and stronger progression and response metrics versus durvalumab plus chemotherapy, give Summit Therapeutics a path to extend ivonescimab into a rare but high‑need setting that could add incremental revenue streams beyond the core lung and colorectal cancer focus…"

Discover why this Narrative puts Summit Therapeutics at 66% undervalued.

Bear case: 18% overvalued

This angle comes from the bearish analyst Narrative on Simply Wall St, which focuses on funding structure, trial breadth and shareholder dilution.

"The decision to fund growing late stage investment and U.S. commercial build out through US$231 million of at the market equity issuance in Q2 2026, plus a new US$380 million program and a US$2b convertible preferred stake from AstraZeneca, points to ongoing dilution risk for common shareholders, which could cap per share earnings even if ivonescimab generates meaningful sales…"

Explore why this Narrative puts Summit Therapeutics at 18% overvalued.

For Summit Therapeutics, the share price is only one piece of the decision

Before you make a call on Summit Therapeutics, it helps to know who is steering the trials, how their incentives line up with yours, and what that might mean for future choices. See who runs Summit Therapeutics and how they are paid.